Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ICONIC
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT03866382 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on ICONIC yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ICONIC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Bladder Adenocarcinoma; Bladder Clear Cell Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Neuroendocrine Carcinoma; Bladder Small Cell Neuroendocrine Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma; Invasive Bladder Giant Cell Urothelial Carcinoma; Invasive Bladder Lymphoepithelioma-Like Carcinoma; Invasive Bladder Nested Urothelial Carcinoma; Invasive Bladder Plasmacytoid Urothelial Carcinoma; Invasive Bladder Sarcomatoid Urothelial Carcinoma; Invasive Bladder Urothelial Carcinoma; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Malignant Testicular Leydig Cell Tumor; Malignant Testicular Sertoli Cell Tumor; Metastatic Bladder Carcinoma; Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma; Metastatic Bladder Giant Cell Urothelial Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Lipid-Rich Urothelial Carcinoma; Metastatic Bladder Micropapillary Urothelial Carcinoma; Metastatic Bladder Plasmacytoid Urothelial Carcinoma; Metastatic Bladder Sarcomatoid Urothelial Carcinoma; Metastatic Bladder Small Cell Neuroendocrine Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Chromophobe Renal Cell Carcinoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Papillary Renal Cell Carcinoma; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Metastatic Urethral Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Urachal Adenocarcinoma; Urethral Clear Cell Adenocarcinoma
- Interventions
- Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography
- Arms
- Treatment (cabozantinib, nivolumab, ipilimumab) · Experimental
- Enrollment
- 314 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 13, 2019
- Primary completion
- Feb 28, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03866382 · updated Oct 30, 2026
Publications
linked from the registry- Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK, Saraiya B, Cordes L, Ley L, Ortiz OS, Cadena J, Diaz C, Bagheri H, Redd B, Steinberg SM, Costello R, Chan KS, Lee MJ, Lee S, Yu Y, Gurram S, Chalfin HJ, Valera V, Figg WD, Merino M, Toubaji A, Streicher H, Wright JJ, Sharon E, Parnes HL, Ning YM, Bottaro DP, Cao L, Trepel JB, Apolo AB. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2022 Apr 1;28(7):1353-1362. doi: 10.1158/1078-0432.CCR-21-3726. PubMed 35031545